Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Sunday.

Supernus Pharmaceuticals Stock Down 3.7%

Shares of NASDAQ:SUPN opened at $32.34 on Friday. The business has a fifty day simple moving average of $32.41 and a 200-day simple moving average of $33.64. Supernus Pharmaceuticals has a 52 week low of $27.05 and a 52 week high of $40.28. The company has a market cap of $1.81 billion, a P/E ratio of 29.14 and a beta of 0.70.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in SUPN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Supernus Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after acquiring an additional 1,083 shares during the last quarter. Two Sigma Advisers LP grew its position in Supernus Pharmaceuticals by 14.7% in the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after purchasing an additional 1,000 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock valued at $10,032,000 after purchasing an additional 9,590 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 6.2% during the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock valued at $2,169,000 after buying an additional 3,495 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Supernus Pharmaceuticals by 63.6% during the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock worth $579,000 after buying an additional 6,867 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.